RNA-U6 small nuclear 990: A Potential Drug Target and Biomarker

Target Name: RNU6-990P

NCBI ID: G106480627

RNU6-990P

Other Name(s): RNA, U6 small nuclear 990, pseudogene

RNA-U6 small nuclear 990: A Potential Drug Target and Biomarker

RNA-U6 small nuclear 990 (RNU6-990P) is a molecule that has gained significant interest due to its potential role in various biological processes. As a pseudogene, RNU6-990P is a non-coding RNA molecule that was identified in the human genome. Its function and potential use as a drug target or biomarker continue to be explored.

The RNA-U6 small nuclear 990 molecule is a single-stranded RNA molecule that contains 990 base pairs. It is characterized by its compact structure, with a single open reading frame (ORF) that encodes a protein with 65 amino acid residues. The ORF is located at the C-end of the RNA molecule, and the molecule has a 5' to 3' orientation.

RNA-U6 small nuclear 990 has been shown to play a critical role in various biological processes, including cell growth, apoptosis, and DNA replication. The molecule is expressed in various tissues and cells of the human body, including the brain, heart, and liver. It has also been found in various biological fluids, including blood, saliva, and urine.

One of the most significant features of RNA-U6 small nuclear 990 is its potential as a drug target. Its compact structure and single-stranded nature make it an attractive target for small molecules, antibodies, or other therapeutic agents. Additionally, its expression in various tissues and cells makes it a promising biomarker for disease diagnosis and treatment.

RNA-U6 small nuclear 990 has been shown to play a role in various cellular processes by regulating gene expression, cell growth, and apoptosis. For example, studies have shown that RNA-U6 small nuclear 990 can inhibit the activity of the oncogene p53, which is a well-known tumor suppressor gene that plays a critical role in preventing cancer growth.

In addition to its potential as a drug target, RNA-U6 small nuclear 990 has also been shown to be a promising biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that RNA-U6 small nuclear 990 levels are elevated in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, the molecule has been shown to be expressed in the brains of individuals with Alzheimer's disease and other neurodegenerative diseases.

The potential use of RNA-U6 small nuclear 990 as a drug target or biomarker continues to be explored. Research is being conducted to identify small molecules or antibodies that can interact with the molecule and enhance its expression. Additionally, efforts are underway to determine the molecular mechanisms that regulate RNA-U6 small nuclear 990 expression and its role in various biological processes.

In conclusion, RNA-U6 small nuclear 990 is a promising molecule that has the potential to be a drug target or biomarker. Its compact structure and single-stranded nature make it an attractive target for small molecules, antibodies, or other therapeutic agents. Additionally, its expression in various tissues and cells of the human body makes it a promising biomarker for disease diagnosis and treatment. Further research is needed to fully understand the molecular mechanisms that regulate RNA-U6 small nuclear 990 expression and its role in various biological processes.

Protein Name: RNA, U6 Small Nuclear 990, Pseudogene

The "RNU6-990P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU6-990P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets